Fuel consumption in the COREX-3000 process run in Baosteel is currently higher than the design index. Therefore, mass and heat balance equations for the COREX process were established using the basic principles in- cl...Fuel consumption in the COREX-3000 process run in Baosteel is currently higher than the design index. Therefore, mass and heat balance equations for the COREX process were established using the basic principles in- cluded in the Rist operating diagram for blast furnace （BF） as a reference. Thermodynamic calculations were then used to modify the Rist operating diagram so that it was suitable for the COREX process. The modified Rist operating dia- gram was then applied for the evaluation of metallization rate （MR） and fuel structure to reduce the energy consump- tion in the COREX process. The modified Rist operating diagram for the shaft furnace （SF） provided a nearly ideal value for the restriction point W when the metallization rate was increased, while the point P on the operating line for the melter gasifier （MG） moved upward due to reduction in the heat required in hearth. The feasibility of reduc- ing the energy consumption during the COREX process by changing the fuel structure was also demonstrated.展开更多
The prognosis for children with recurrent or refractory neuroblastoma remains a significant clinical challenge,and currently there are no known curative salvage regimens.In this paper we investigated the effect of ima...The prognosis for children with recurrent or refractory neuroblastoma remains a significant clinical challenge,and currently there are no known curative salvage regimens.In this paper we investigated the effect of imatinib with rapamycin and the chemotherapeutic agents temozolomide and irinotecan.We treated two children with recurrent neuroblastoma with this so called RIST protocol.Both patients,off therapy for 15 and 31 months,respectively are well,and developing normally,without any complications.These findings suggest that a combination regimen of RIST may provide a therapeutic benefit with a favorable toxicity profile to a unfortunate subset of patients with neuroblastoma.展开更多
基金Item Sponsored by National Natural Science Foundation of China(50934007,50874129)National High-tech Research and Development Program of China(2009AA06Z105)+1 种基金Special Research Foundation of Young Teachers of University of Science and Technology Liaoning of China(2014QN30)Foundation of Liaoning Educational Committee of China(L2015264)
文摘Fuel consumption in the COREX-3000 process run in Baosteel is currently higher than the design index. Therefore, mass and heat balance equations for the COREX process were established using the basic principles in- cluded in the Rist operating diagram for blast furnace （BF） as a reference. Thermodynamic calculations were then used to modify the Rist operating diagram so that it was suitable for the COREX process. The modified Rist operating dia- gram was then applied for the evaluation of metallization rate （MR） and fuel structure to reduce the energy consump- tion in the COREX process. The modified Rist operating diagram for the shaft furnace （SF） provided a nearly ideal value for the restriction point W when the metallization rate was increased, while the point P on the operating line for the melter gasifier （MG） moved upward due to reduction in the heat required in hearth. The feasibility of reduc- ing the energy consumption during the COREX process by changing the fuel structure was also demonstrated.
文摘The prognosis for children with recurrent or refractory neuroblastoma remains a significant clinical challenge,and currently there are no known curative salvage regimens.In this paper we investigated the effect of imatinib with rapamycin and the chemotherapeutic agents temozolomide and irinotecan.We treated two children with recurrent neuroblastoma with this so called RIST protocol.Both patients,off therapy for 15 and 31 months,respectively are well,and developing normally,without any complications.These findings suggest that a combination regimen of RIST may provide a therapeutic benefit with a favorable toxicity profile to a unfortunate subset of patients with neuroblastoma.
